Literature DB >> 17030663

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.

Hanna Rosenmann1, Nikolaos Grigoriadis, Dimitrios Karussis, Moran Boimel, Olga Touloumi, Haim Ovadia, Oded Abramsky.   

Abstract

BACKGROUND: A possible role of autoimmunity in Alzheimer disease pathogenesis has recently attracted increasing attention. Vaccination with amyloid-beta peptide was reported to cause marked reduction in amyloid deposition, but it also induced encephalitis. Not much is known regarding neurofibrillary tangle-related autoimmune effects.
OBJECTIVE: To use the main component of tangles-microtubule-associated tau protein-to test the feasibility of active induction of a neuroautoimmune disorder in mice.
DESIGN: Prospective, randomized controlled animal study.
SETTING: University medical center research laboratory. Subjects Female C57BL/6 mice.
INTERVENTIONS: Inoculation with recombinant human tau protein emulsified in complete Freund adjuvant and with pertussis toxin. MAIN OUTCOME MEASURES: Clinical, immunologic, pathologic, and behavioral evaluations were performed.
RESULTS: Vaccination with tau protein induced histopathologic features of Alzheimer disease and tauopathies, indicated by the presence of neurofibrillary tangle-like structures, axonal damage, and gliosis. Also, mononuclear infiltrates without demyelination in the central nervous system, accompanied by neurologic deficits (such as a limp tail and limb paralysis), were observed. Anti-tau antibodies were detected in the serum of tau-immunized mice.
CONCLUSIONS: These results provide a link between tau autoimmunity and tauopathy-like abnormalities and indicate potential dangers of using tau for immunotherapy. This experimental autoimmune tauopathy-like model is due to a pathogenic immune response against an intraneuronal antigen and is not related to myelin antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030663     DOI: 10.1001/archneur.63.10.1459

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  77 in total

Review 1.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Therapy for Alzheimer's Disease: How Effective are Current Treatments?

Authors:  Krista L Lanctôt; Ryan D Rajaram; Nathan Herrmann
Journal:  Ther Adv Neurol Disord       Date:  2009-05       Impact factor: 6.570

3.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

Review 4.  Tau immunotherapy and imaging.

Authors:  Einar M Sigurdsson
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

5.  Recent advances in the development of immunotherapies for tauopathies.

Authors:  Kiren Ubhi; Eliezer Masliah
Journal:  Exp Neurol       Date:  2010-10-21       Impact factor: 5.330

6.  Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease.

Authors:  Monica Marchese; David Cowan; Elizabeth Head; Donglai Ma; Khalil Karimi; Vanessa Ashthorpe; Minesh Kapadia; Hui Zhao; Paulina Davis; Boris Sakic
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

Review 7.  Tau-focused immunotherapy for Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  Curr Alzheimer Res       Date:  2009-10       Impact factor: 3.498

Review 8.  Alzheimer disease therapy--moving from amyloid-β to tau.

Authors:  Ezio Giacobini; Gabriel Gold
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 10.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.